Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03266848 · ClinicalTrials.gov registry record

Quantitative Non-Invasive Brain Imaging Using QUTE-CE MRI

A clinical trial of Cerebrovascular Disorders, sponsored by Theranano.

Completed
Registry status
15
Enrollment target
1
Study location

NCT03266848: Completed study of Cerebrovascular Disorders, sponsored by Theranano.

NCT03266848 is a study of Cerebrovascular Disorders that has completed, run by Theranano. The registered enrollment target is 15 participants, below the 1,095-participant average among 8 other Cerebrovascular Disorders trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03266848, a study of Cerebrovascular Disorders, has completed, sponsored by Theranano.

COMPLETED
Registry status
15 participants
Enrollment target
1
Study location

Study Summary

This trial will evaluate a non-invasive brain imaging technique QUTE-CE MRI and validate the method with first-in-human studies.

Primary Outcome

Obtain angiograms of the cerebral vasculature from the MRI intensity data

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST Quantitative Magnetic Resonance Imaging

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2017-11-08
Est. Completion 2020-07-22
Theranano

1 total trials

What the finished NCT03266848 record still lists

NCT03266848 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 1,095-participant average among 8 other Cerebrovascular Disorders trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Cerebrovascular Disorders appearing as the primary indexed condition, and to 1 intervention - of which Quantitative Magnetic Resonance Imaging is the first listed.

NCT03266848 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03266848 about?

NCT03266848 is a clinical study titled "Quantitative Non-Invasive Brain Imaging Using QUTE-CE MRI". This trial will evaluate a non-invasive brain imaging technique QUTE-CE MRI and validate the method with first-in-human studies.

What is the current status of trial NCT03266848?

This trial is currently completed. The enrollment target is 15 participants. The study started on 2017-11-08. Estimated completion is 2020-07-22.

What conditions does trial NCT03266848 study?

This clinical trial studies the following conditions: Cerebrovascular Disorders.

What interventions are being tested in trial NCT03266848?

The interventions under investigation include: Quantitative Magnetic Resonance Imaging (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT03266848?

This trial is sponsored by Theranano, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03266848 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cerebrovascular Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03266848's enrollment target sits among peer trials

15 9th of 8 the lowest of 8 other Cerebrovascular Disorders trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cerebrovascular Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03266848, the US trial registry maintained by the National Library of Medicine. NCT03266848 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.